LCTX
insider transactionsLineage Cell Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+15.0K
15.0K buy · 0 sell
Net value · 365d
$24.4K
$24.4K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
1
15.0K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Brian M Culley KEY
President and CEO
$24.4K
15.0K sh · $1.63
Own +6%
-
Grant·A
General Counsel and Secretary
$0
900.0K sh
Own New
-
Grant·A
Jill Ann Howe KEY
Chief Financial Officer
$0
1.1M sh
Own New
-
Grant·A
Brian M Culley KEY
President and CEO
$0
3.2M sh
Own New
-
Exercise·M
General Counsel and Secretary
$0
6.1K sh
Own New
-
Other·F
General Counsel and Secretary
$4.5K
2.5K sh · $1.80
Own -7%
-
Exercise·M
General Counsel and Secretary
—
6.1K sh
Own +22%
-
Exercise·M
Brian M Culley KEY
President and CEO
$0
31.2K sh
Own New
-
Other·F
Brian M Culley KEY
President and CEO
$23.2K
12.9K sh · $1.80
Own -5%
-
Exercise·M
Brian M Culley KEY
President and CEO
—
31.2K sh
Own +14%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 12, 2026 | Brian M Culley KEY | Buy P | 15.0K | $24.4K |
| Mar 5, 2026 | George A. Samuel III | Grant A | 900.0K | $0 |
| Mar 5, 2026 | Jill Ann Howe KEY | Grant A | 1.1M | $0 |
| Mar 5, 2026 | Brian M Culley KEY | Grant A | 3.2M | $0 |
| Feb 11, 2026 | George A. Samuel III | Exercise M | 6.1K | $0 |
| Feb 11, 2026 | George A. Samuel III | Other F | 2.5K | $4.5K |
| Feb 11, 2026 | George A. Samuel III | Exercise M | 6.1K | — |
| Feb 11, 2026 | Brian M Culley KEY | Exercise M | 31.2K | $0 |
| Feb 11, 2026 | Brian M Culley KEY | Other F | 12.9K | $23.2K |
| Feb 11, 2026 | Brian M Culley KEY | Exercise M | 31.2K | — |
About LCTX insider trading
This page tracks insider transactions for Lineage Cell Therapeutics, Inc. (LCTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.